Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanara MedTechSMTI +13.59%74 Forward PE Ratio is 177.94 as of Jul. 30, 2026. GuruFocus rates SMTI with a GF Score™ of 74/100 and a GF Value™ of $45.93 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 390 Medical Devices & Instruments companies, Sanara MedTech ranks worse than 95.9% on this metric.
Sanara MedTech (NAS:SMTI) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Sanara MedTech Forward PE Ratio Related Terms
Sanara MedTech Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Sanara MedTech's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanara MedTech Forward PE Ratio Chart
Sanara MedTech Annual Data
Trend
2025-12
Forward PE Ratio
19.61
Sanara MedTech Quarterly Data
2025-12
2026-03
Forward PE Ratio
19.61
26.09
SMTI vs UTMD, OSUR, EMBC: Forward PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, Sanara MedTech's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Sanara MedTech (SMTI) has a Forward PE Ratio of 177.94 as of Jul. 30, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Sanara MedTech and its competitors. According to the industry distribution chart, Sanara MedTech ranks #374 out of 390 companies in the Medical Devices & Instruments industry, placing it in the top 95.9%.
Is Sanara MedTech's Forward PE Ratio too high?
Sanara MedTech's current Forward PE Ratio is 177.94. The Medical Devices & Instruments industry median Forward PE Ratio is 19.18. Sanara MedTech's value of 177.94 is 827.7% above this industry median. Based on the distribution chart, Sanara MedTech ranks #374 out of 390 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sanara MedTech has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's Forward PE Ratio compare to UTMD and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Sanara MedTech ranks #374 out of 390 companies for Forward PE Ratio. This places Sanara MedTech in the lower half of its industry. The industry median Forward PE Ratio is 19.18. Sanara MedTech's value of 177.94 is 827.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.18, based on 390 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanara MedTech's current Forward PE Ratio of 177.94 is 827.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Sanara MedTech and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanara MedTech's current Forward PE Ratio is 177.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.93, compared to a current price of $30.25 — trading 34.1% below its estimated fair value. The current Forward PE Ratio is 177.94 and 827.7% above the Medical Devices & Instruments industry median of 19.18. Sanara MedTech's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current Forward PE Ratio is 177.94 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $30.25 is trading 34.1% below its estimated GF Value™ of $45.93.
GuruFocus considers Sanara MedTech to be Possible Value Trap.
Key valuation signals for SMTI:
Forward PE Ratio: 177.94
GF Value™: $45.93 vs. price of $30.25 (34.1% below fair value)
Industry Position: 827.7% above the Medical Devices & Instruments median (#374 of 390)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
74GF Score
Get the complete analysis for SMTI
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
